Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

@article{Cella2006QualityOL,
  title={Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer},
  author={D. Cella and L. Fallowfield and P. Barker and J. Cuzick and G. Locker and A. Howell and On behalf of the Atac Trialistsȁ9 Group},
  journal={Breast Cancer Research and Treatment},
  year={2006},
  volume={100},
  pages={273-284}
}
  • D. Cella, L. Fallowfield, +4 authors On behalf of the Atac Trialistsȁ9 Group
  • Published 2006
  • Medicine
  • Breast Cancer Research and Treatment
  • The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer. Here we report mature HRQoL outcomes from the ATAC trial, comparing anastrozole with tamoxifen as primary adjuvant therapy for postmenopausal women with localized breast cancer. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire plus endocrine subscale (ES) at baseline, 3 and 6 months, and every 6 months… CONTINUE READING
    205 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This study evaluates the effects of progressive relaxation exercises on artralgia, quality of life and anxiety in breast cancer survivors receiving aromatase inhibitors. Half of the… Expand
    ConditionsBreast Cancer
    InterventionOther
    Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer
    • 14
    • Highly Influenced

    References

    SHOWING 1-10 OF 19 REFERENCES
    Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
    • 268
    Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
    • 175
    A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    • 1,710
    • PDF
    Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
    • T. Whelan, P. Goss, +9 authors H. Muss
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2005
    • 227
    Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT‐B
    • 261
    • Highly Influential
    Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.
    • 269
    Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
    • J. Cuzick
    • Medicine
    • Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
    • 2003
    • 79